Carregant...
Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis
AIM: To determine the efficacy and safety of certolizumab pegol for the treatment of rheumatoid arthritis in a real-world setting. MATERIALS & METHODS: Patients with moderate-to-severe rheumatoid arthritis who initiated therapy with certolizumab were followed for 12 weeks. Response was assessed...
Guardat en:
| Publicat a: | Future Sci OA |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Future Science Ltd
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5905631/ https://ncbi.nlm.nih.gov/pubmed/29682324 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4155/fsoa-2017-0149 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|